

# A Prospective Cohort Study providing Insights for Markers of Adverse Pregnancy Outcome in Women of Advanced Maternal Age

**Samantha Lean**

University of Manchester

**Rebecca Jones**

University of Manchester

**Stephen Roberts**

University of Manchester

**Alexander Hezell** (✉ [alexander.hezell@manchester.ac.uk](mailto:alexander.hezell@manchester.ac.uk))

University of Manchester

---

## Research Article

**Keywords:** Aging, biomarkers, hormones, inflammation, oxidative stress, stillbirth, placental dysfunction.

**Posted Date:** December 30th, 2020

**DOI:** <https://doi.org/10.21203/rs.3.rs-130070/v1>

**License:** © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

---

# Abstract

**Background** Advanced maternal age (AMA;  $\geq 35$  years) is associated with increased rates of adverse pregnancy outcome. Better understanding of underlying pathophysiological processes may improve identification of AMA mothers who are at greatest risk of adverse outcome. This study aimed to investigate changes in oxidative stress and inflammation in AMA women and identify clinical and biochemical predictors of adverse pregnancy outcome in women of AMA.

**Methods** The Manchester Advanced Maternal Age Study (MAMAS) was a multicentre, observational, prospective cohort study of 527 mothers. Participants were divided into three age groups for comparison 20-30 years ( $n=158$ ), 35-39 years ( $n=212$ ) and  $\geq 40$  years ( $n=157$ ). Demographic and medical data were collected along with maternal blood samples at 28 and 36 weeks' gestation. Multivariable analysis was conducted to identify variables associated with adverse outcome, defined as one or more of: small for gestational age ( $< 10^{\text{th}}$  centile), FGR ( $< 5^{\text{th}}$  centile), stillbirth, NICU admission, preterm birth  $< 37$  weeks gestation or Apgar score  $< 7$  at 5 minutes. Biomarkers of inflammation, oxidative stress and placental dysfunction were quantified in maternal serum. Univariate and multivariable statistical analyses were used to identify associations with composite adverse fetal outcome.

**Results:** Maternal smoking was associated with adverse outcome in older mothers (Adjusted Odds Ratio (AOR) 4.34, 95% Confidence Interval (95%CI) 1.88, 9.99), whereas multiparity reduced the odds (AOR 0.56, 95% CI 0.34, 0.99). In uncomplicated AMA pregnancies, lower circulating anti-inflammatory IL-10, IL-1RA and increased antioxidant capacity (TAC) were seen. In AMA with adverse outcome, TAC and oxidative stress markers were increased and levels of maternal circulating placental hormones (hPL, PIGF and sFlt-1) were reduced ( $p < 0.05$ ). Of these, placental growth factor had the strongest predictive accuracy (Area Under the Receiver Operator Characteristic (AUROC) = 0.74) followed by TAC (AUROC=0.69).

**Conclusions:** This study identified alterations in circulating inflammatory and oxidative stress markers in AMA women and in AMA women with adverse pregnancy outcome providing preliminary evidence of mechanistic links. Further, larger studies are required to determine if these markers can be developed into a predictive model of an individual AMA woman's risk of APO, enabling a reduction in stillbirth rates whilst minimising unnecessary intervention.

## Introduction

Advanced maternal age (AMA,  $\geq 35$  years) is a growing trend in high income countries (1, 2). Large epidemiological studies and subsequent meta-analysis have identified AMA as an independent risk factor for adverse fetal outcomes including: fetal growth restriction (FGR), pre-term birth (PTB), pre-eclampsia (PE), neonatal intensive care unit (NICU) admission and stillbirth (3–8). Stillbirths in AMA are likely to occur near term with risks comparable to those in obesity, smoking, diabetes or history of stillbirth (9–11). However, unlike these conditions there are few guidelines to reduce adverse outcomes (12, 13).

There is international recognition that women of AMA should undergo additional antepartum screening or intervention to address the increased risk of stillbirth (14–17). The RCOG and SOGC recommend offering induction of labour (IOL) at 39 weeks and/or additional monitoring from 38 weeks' gestation (2, 15, 18).

Although not associated with an increase in the rate of Caesarean Sect. (19), IOL may be viewed as an unnecessary intervention as the majority of mothers will have uncomplicated pregnancies. Furthermore, induction may not be an acceptable intervention for women of AMA without further indication, with poor recruitment (only 13.6%) of eligible women to the 35–39 trial consenting to be randomised (19). Identification of mothers with highest risk would result in fewer interventions to prevent stillbirths.

Many pregnancy pathologies are associated with changes in oxidative stress and inflammatory status (20–22). Similar changes are reported in aging processes although these are usually researched in older populations (23, 24). If these alterations were present in AMA they could adversely affect placental function (25–27). Previous work found evidence of placental dysfunction in AMA pregnancies including (but not limited to) reduced amino acid transport, aberrant cell turnover and reduced placental efficiency (28). Therefore, it was hypothesised that the increased risk of adverse pregnancy outcome results from an aging maternal environment and that a combination of biomarkers of aging, placental dysfunction, and clinical risk factors might identify women at greatest risk. This study aimed to determine whether there were changes in oxidative stress and inflammation in AMA pregnancies and whether changes in these biomarkers were evident in adverse pregnancy outcomes in this population.

## Methods

Women were recruited to the Manchester Advanced Maternal Age Study (MAMAS) from March 2012- October 2014 from six UK maternity units after providing written informed consent. Ethical approval was obtained from the NRES Committee North West, (12/NW/0015). Pregnant women aged between 20–30 years (controls – optimal reproductive age), 35–39 years and  $\geq 40$  years were approached at 28 weeks' gestation between April 2012-June 2014. Women with multiple pregnancy, body mass index (BMI)  $< 18.5$  or  $> 30$  kg/m<sup>2</sup>, fetal abnormalities, and pre-existing maternal medical conditions were excluded. We estimated a 20% incidence of adverse pregnancy outcome (APO), therefore approximately 600 participants were required to obtain 120 women with APO; 120 women with APO would allow multivariable analysis of six covariates.

In addition to usual antenatal care, participants attended prenatal research appointments at 28 and 36 weeks' gestation ( $\pm 1$  week), at which detailed demographic, medical data and maternal blood samples for plasma and serum fractionation were collected. After delivery, outcome data were collected from medical records. Biochemical analyses were conducted after delivery, therefore not altering participants' prenatal care.

The Index of Multiple Deprivation (IMD) – a measure of relative social deprivation (29) - was calculated from the mother's address using NPEU-IMD tool (University of Oxford, UK). A composite adverse pregnancy outcome (APO) was defined as one or more: small for gestational age (SGA) or FGR ( $< 10$ th / $< 5$ th centile respectively using individualised birthweight centiles (IBC) (30), stillbirth, admission to the NICU, PTB without infection ( $< 37$  weeks gestation), and 5 minute Apgar score  $< 7$  in the absence of maternal diseases (diabetes/hypertension). Normal pregnancy outcome was defined as a term live birth (38–42 weeks), appropriately grown (IBC between 10-95th centile) and absence of maternal or fetal complication (not limited just to those included in our APO definition).

## Nested Case Control Studies

Two nested case-control studies were conducted i) to determine whether AMA associated with elevated circulating biomarkers of inflammation and oxidative stress and ii) to determine whether APO was associated with markers of aging and placental dysfunction in women  $\geq 35$  years of age. In the first nested case-control study samples from participants  $\geq 40$  years were matched (1:1) to mothers aged 20–30 and 35–39 years ( $n = 40/\text{group}$ ) for demographic (BMI, IMD, ethnicity (groups), marital status (married, single, partnership), smoking status (current/ex/non-smoker) and obstetric characteristics (normal vaginal delivery (NVD)). Women with adverse pregnancy outcome, who conceived via assisted reproductive technology (ART) or in whom maternal disease that developed post 28 weeks' gestation were excluded. Sample sizes were determined following power calculations based on previous studies for detecting a difference in circulating oxidative stress (31–34) and inflammatory mediators (35–37). For example, to detect a difference in cytokines TNF- $\alpha$  and IL-6 between normal and adverse outcomes in AMA with 80% power with a 5% significance level required between 28 and 43 participants in each group.

For the second nested case control study, cases were 43 women  $\geq 35$  years of age who had an APO as defined above. Controls were participants with maternal age  $\geq 35$  years without an APO. Participants that had maternal disease that developed post 28 weeks, PTB associated with infection, or incomplete outcome data were excluded. Groups were matched for demographic characteristics (maternal/paternal age, ethnicity, BMI, smoking status, marital and housing (ownership/rental) status and parity (primi/multiparous).

Biomarkers of aging were measured in maternal serum or plasma samples for participants included in the nested case control studies (Supplementary Table 1). Absorbances were measured using a microplate reader (FLUOStarOmega, BMG Labtech) for all Enzyme linked immunosorbent assays (ELISAs). Pro/anti-inflammatory cytokines (interleukin (IL)-1 $\alpha$ , IL-1 $\beta$ , IL-1Ra, IL-6, IL-10 and tumour necrosis factor (TNF)- $\alpha$ ) were quantified in maternal serum using DuoSet® ELISAs (R&D Systems, Abingdon, UK) following an optimised protocol (27).

Maternal plasma antioxidant concentration was quantified using OxiSelect™ Total Antioxidant Capacity Assay Kit (Cell Biolabs, Inc., San Diego, USA). Oxidative damage markers 8-Isoprostane and DNA/RNA oxidative damage were measured by EIA Kits and Protein Carbonyl Calorimetric Assay Kit (Cayman Chemical Company, Michigan, USA). Maternal serum placental hormones (hCG, PAPP-A, Progesterone and hPL were quantified using DRG ELISA kits (DRG Instruments, Marburg, Germany). Placental growth factor (PIGF) and soluble fms-like tyrosine kinase-1 (sFlt) were quantified using DuoSet® ELISAs (R&D systems). All assays were conducted according to the manufacturer's standard protocols.

## Statistical analysis

Demographic data were compared using Fisher's Exact test for categorical data and Kruskal-Wallis tests with Dunn's multiple comparisons or Mann Whitney U tests for continuous data. Univariate logistic regression was conducted on the whole dataset to identify demographic or clinical variables associated with APO.

Multivariable logistic regression was used to quantify the effect of maternal age on APO; in this analysis maternal ethnicity, use of ART, smoking status, parity, IMD and home ownership were included as categorical variables and in a second model, paternal age was included as an additional categorical variable (< 30, 30–34, 35–39 and 40+ years). The logistic regression analyses were conducted using STATA (Version 14, StataCorp, Texas, USA). Biomarker analysis was performed on GraphPad Prism (Version 6.04, GraphPad

Software Inc., La Jolla, USA) using Kruskal-Wallis with Dunn's multiple comparisons tests on untransformed data or Mann-Whitney U where appropriate. Due to wide dispersion in the cytokine data, including values at the lower limit of detection of the assay, these data were transformed as  $\log(y + \text{smallest detectable value})$  for analysis. Gestational age effects were assessed using Spearman's correlation. Markers that showed statistical significance at the  $p < 0.01$  level were analysed to test their predictive potential as markers of APO in women aged  $\geq 35$  years by calculation of the area under the receiver operator characteristic curve (AUROC).

## Results

Overall, 1,134 women were approached to participate in MAMAS. 585 of these mothers (51%) either did not meet the inclusion criteria or declined to participate (Fig. 1). 549 mothers consented before 28 weeks gestation. A further 40 participants were recruited between 28 weeks' gestation and delivery. 62 mothers (11%) were either lost to follow up or withdrew from the study between 28 weeks' gestation and delivery. Therefore, demographic, medical and pregnancy data was collected on a final cohort of 527 participants ( $n = 158$  20–30,  $n = 212$  35–39 and  $n = 157 \geq 40$  year olds).

There were no differences between ethnicity, employment and deprivation between participants in different age groups (Table 1). Paternal age was higher in pregnancies to mothers 35–39 and  $\geq 40$  years, and mothers  $\geq 40$  years had higher BMI ( $p = 0.0025$ ) compared to 20–30 year olds ( $p < 0.0001$ ). More mothers aged 35–39 years were married, and more mothers  $\geq 40$  years were in partnerships than the other maternal age groups ( $p = 0.003$ ). More AMA mothers were non-smokers ( $p = 0.047$ ), homeowners ( $p < 0.001$ ), multiparous ( $p = 0.0005$ ), previous FGR ( $p = 0.022$ , 35–39 years only) and had previous or current fertility treatment (predominantly in vitro fertilisation,  $p < 0.001$ ) compared to controls. Of those who conceived using assisted reproductive technologies, 47% of those  $\geq 40$  years used egg and/or sperm donors, compared to 8% of 35–39 year olds.

Table 1  
Demographic data for total MAMAS participants.

Demographics	20–30 Years (n = 158)	35–39 Years (n = 212)	≥ 40 Years (n = 157)	<i>p</i> value Overall	<i>p</i> value Multiple Comparisons
Maternal age	<b>26</b> (20–30)	<b>37</b> (35–39)	<b>42</b> (40–49)		
Paternal Age <sup>a</sup>	<b>29</b> (18–48)	<b>38</b> (21–50)	<b>43</b> (25–60)	<b>&lt; 0.0001</b>	<sup>†</sup> <sup>‡</sup> <b>&lt;0.0001</b>
BMI (kg/m <sup>2</sup> ) <sup>a</sup>	<b>23.8</b> (18.7–29.9)	<b>24.1</b> (18.5–29.9)	<b>25.0</b> (19.0–29.8)	<b>0.0024</b>	<sup>†</sup> 0.95, <sup>‡</sup> <b>0.0025</b> , <sup>Δ</sup> <b>0.027</b>
Ethnicity <sup>b</sup>	<b>88%</b> (144)	<b>79%</b> (168)	<b>92%</b> (144)	0.23	
<i>European</i>					
Marital Status <sup>b</sup>	<b>4%</b> (7)	<b>2%</b> (5)	<b>4%</b> (6)	<b>0.003</b>	<sup>†</sup> <b>&lt;0.001</b> , <sup>‡</sup> 0.18, <sup>Δ</sup> 0.21
<i>Single</i>	<b>41%</b> (65)	<b>62%</b> (131)	<b>37%</b> (58)		
<i>Married/CP</i>	<b>47%</b> (74)	<b>31%</b> (66)	<b>52%</b> (81)		
<i>Partner</i>	<b>8%</b> (12)	<b>5%</b> (10)	<b>7%</b> (12)		
<i>Other</i>					
Occupation <sup>b</sup>	<b>76%</b> (120)	<b>79%</b> (167)	<b>75%</b> (117)	0.65	
<i>Employed</i>	<b>17%</b> (27)	<b>15%</b> (31)	<b>16%</b> (25)		
<i>Unemployed</i>	<b>7%</b> (11)	<b>6%</b> (14)	<b>9%</b> (15)		
<i>Unknown</i>					

Data are mean (range) or percentage (number). BMI = body mass index, CP = civil partnership, IMD = index of multiple deprivation, APO = adverse pregnancy outcome, ART = assisted reproductive therapies, IVF = in vitro fertilisation, Donor = egg and/or sperm, IUI = intrauterine insemination. Statistical differences are <sup>a</sup>Kruskal-Wallis with Dunn's multiple comparisons or <sup>b</sup>Fishers exact test. When overall *p* > 0.05, multiple comparisons *p* values are reported (<sup>†</sup> 20–30 vs. 35–39 years, <sup>‡</sup> 20–30 vs ≥ 40 years, <sup>Δ</sup> 35–39 vs. ≥40 years). Significant differences are highlighted with **bold** *p* values

Demographics	20–30 Years (n = 158)	35–39 Years (n = 212)	≥ 40 Years (n = 157)	<i>p</i> value Overall	<i>p</i> value Multiple Comparisons
Smoking Status <sup>b</sup>	<b>72%</b> (113)	<b>77%</b> (163)	<b>83%</b> (130)	<b>0.047</b>	<sup>†</sup> 0.12, <sup>¶</sup> <b>0.021</b> , <sup>Δ</sup> 0.25
<i>Non-smoker</i>	<b>11%</b> (17)	<b>6%</b> (11)	<b>3%</b> (5)		
<i>Current</i>	<b>17%</b> (28)	<b>17%</b> (37)	<b>14%</b> (21)		
<i>Ex-smoker</i>					
Housing <sup>b</sup>	<b>40%</b> (63)	<b>40%</b> (107)	<b>78%</b> (122)	<b>&lt; 0.001</b>	<sup>†</sup> <b>0.043</b> , <sup>¶</sup> <b>Δp &lt; 0.001</b>
<i>Owns</i>					
IMD <sup>a</sup>	<b>18.89</b>	<b>16.11</b>	<b>15.54</b>	0.25	
<i>Score</i>					
	(2.28–71.95)	(1.94–76.09)	(1.94–73.53)		
Parity <sup>b</sup>	<b>50%</b> (79)	<b>29%</b> (61)	<b>32%</b> (52)	<b>&lt; 0.001</b>	<sup>†</sup> <b>0.0001</b> , <sup>¶</sup> 0.37, <sup>Δ</sup> <b>0.0024</b>
<i>Primiparous</i>	<b>50%</b> (79)	<b>70%</b> (148)	<b>63%</b> (99)		
<i>Parous</i>	<b>0%</b> (0)	<b>1%</b> (3)	<b>4%</b> (6)		
<i>Grandmultiparous</i>					
<p>Data are mean (range) or percentage (number). BMI = body mass index, CP = civil partnership, IMD = index of multiple deprivation, APO = adverse pregnancy outcome, ART = assisted reproductive therapies, IVF = in vitro fertilisation, Donor = egg and/or sperm, IUI = intrauterine insemination. Statistical differences are <sup>a</sup>Kruskal-Wallis with Dunn's multiple comparisons or <sup>b</sup>Fishers exact test. When overall <i>p</i> &gt; 0.05, multiple comparisons <i>p</i> values are reported (<sup>†</sup> 20–30 vs. 35–39 years, <sup>¶</sup> 20–30 vs ≥ 40 years, <sup>Δ</sup> 35–39 vs. ≥40 years). Significant differences are highlighted with <b>bold</b> <i>p</i> values</p>					

Demographics	20–30 Years (n = 158)	35–39 Years (n = 212)	≥ 40 Years (n = 157)	<i>p</i> value Overall	<i>p</i> value Multiple Comparisons
Previous APO <sup>b</sup>	<b>16%</b> (26)	<b>24%</b> (50)	<b>22%</b> (34)	0.24	<sup>†</sup> <b>0.022</b> , <sup>¶</sup> 0.66, <sup>Δ</sup> 0.063
<i>FGR</i>	<b>6%</b> (11)	<b>15%</b> (31)	<b>8%</b> (13)	<b>0.046</b>	
<i>Stillbirth</i>	<b>&lt; 1%</b> (1)	<b>2%</b> (5)	<b>2%</b> (3)	0.63	
Previous ART <sup>b</sup>	<b>&lt; 1%</b> (1)	<b>9%</b> (20)	<b>20%</b> (31)	<b>&lt; 0.001</b>	<sup>†</sup> <b>0.0003</b> , <sup>¶</sup> <b>0.0001</b> , <sup>Δ</sup> <b>0.0045</b>
ART <sup>b</sup>	<b>1%</b> (2)	<b>10%</b> (22)	<b>14%</b> (22)	<b>&lt; 0.001</b>	<sup>†</sup> <b>0.0004</b> , <sup>¶</sup> <b>0.0001</b> , <sup>Δ</sup> 0.29
<i>Hormonal</i>	<b>1%</b> (2)	<b>3%</b> (7)	<b>2%</b> (3)		
<i>IVF</i>	<b>0%</b> (0)	<b>6%</b> (12)	<b>12%</b> (19)		
<i>IVF - Donor</i>	<b>0%</b> (0)	<b>&lt; 1%</b> (1)	<b>6%</b> (9)		
<i>IUI</i>	<b>0%</b> (0)	<b>1%</b> (2)	<b>0%</b> (0)		
<p>Data are mean (range) or percentage (number). BMI = body mass index, CP = civil partnership, IMD = index of multiple deprivation, APO = adverse pregnancy outcome, ART = assisted reproductive therapies, IVF = in vitro fertilisation, Donor = egg and/or sperm, IUI = intrauterine insemination. Statistical differences are <sup>a</sup>Kruskal-Wallis with Dunn's multiple comparisons or <sup>b</sup>Fishers exact test. When overall <i>p</i> &gt; 0.05, multiple comparisons <i>p</i> values are reported (<sup>†</sup> 20–30 vs. 35–39 years, <sup>¶</sup> 20–30 vs ≥ 40 years, <sup>Δ</sup> 35–39 vs. ≥40 years). Significant differences are highlighted with <b>bold</b> <i>p</i> values</p>					

AMA women delivered moderately earlier than women aged 20–30 years (39 weeks + 1 day vs. 39 weeks + 5 days; *p* < 0.001; Table 2). Women ≥ 40 years had a 38% rate of IOL compared to 25–30% in the younger groups (*p* = 0.0065). Fewer AMA mothers had NVDs (*p* = 0.0012) and more had elective or emergency caesarean sections (*p* = 0.013 and 0.037 respectively). Birthweight, IBC and the incidence of pregnancy-related maternal disease did not differ between the maternal age groups. AMA women had lower incidence of normal pregnancy outcome (81% of 20–30 year olds vs only 71% and 65% of women aged 35–39 and ≥ 40 years respectively (*p* = 0.006)). Four women in MAMAS had a stillbirths (between 38<sup>+1</sup> and 40<sup>+3</sup> weeks gestation), all were ≥ 40 year old (*p* = 0.014).

Table 2  
Pregnancy outcome of MAMAS participants

Pregnancy Outcome	20–30 Years (n = 158)	35–39 Years (n = 212)	≥ 40 Years (n = 157)	p value Overall	p Value Multiple Comparisons
Gestation at Delivery <sup>a</sup> Weeks + days	<b>39 + 5</b> (34 + 1–42 + 2)	<b>39 + 3</b> (30 + 5–43 + 1)	<b>39 + 1</b> (30 + 1–42 + 4)	<b>&lt; 0.001</b>	<sup>†</sup> <b>0.043</b> , <sup>¶</sup> <b>&lt;0.0001</b> , <sup>Δ</sup> 0.12
Birthweight (g) <sup>a</sup>	<b>3401</b> (1880–4680)	<b>3387</b> (1300–4900)	<b>3375</b> (1480–4560)	0.72	—
Individualised Birthweight Centile <sup>a</sup>	<b>45.1</b> (0.1–98.7)	<b>47.3</b> (0.0–99.6)	<b>47.7</b> (0.0–99.8)	0.66	—
Induction of Labour <sup>b</sup>	<b>30%</b> (48)	<b>25%</b> (53)	<b>38%</b> (60)	<b>0.024</b>	<sup>†</sup> 0.25, <sup>¶</sup> 0.14, <sup>Δ</sup> <b>0.0065</b>
Mode of Delivery <sup>b</sup>	<b>60%</b> (94)	<b>50%</b> (105)	<b>39%</b> (61)	<b>0.001</b>	<sup>†</sup> <b>0.009</b> , <sup>¶</sup> <b>&lt;0.001</b> , <sup>Δ</sup> 0.12
<i>Normal Vaginal Delivery</i>	<b>13%</b> (21)	<b>25%</b> (52)	<b>25%</b> (40)		
<i>Elective Caesarean Section</i>	<b>8%</b> (11)	<b>10%</b> (22)	<b>17%</b> (25)		
<i>Emergency Caesarean Section</i>	<b>19%</b> (32)	<b>15%</b> (33)	<b>19%</b> (31)		
<i>Instrumental Vaginal Delivery</i>					
Maternal Disease <sup>b</sup>	<b>4%</b> (7)	<b>1%</b> (2)	<b>4%</b> (6)	0.23	
<i>Preeclampsia</i>	<b>&lt; 1%</b> (1)	<b>2%</b> (5)	<b>2%</b> (3)	0.87	
<i>Gestational Diabetes Mellitus</i>					
NPO <sup>b</sup>	<b>81%</b> (128)	<b>71%</b> (150)	<b>65%</b> (102)	<b>0.006</b>	<sup>†</sup> <b>0.024</b> , <sup>¶</sup> <b>0.0013</b> , <sup>Δ</sup> 0.24

Data are mean (range) or percentage (number). Statistical differences are <sup>a</sup>Kruskal-Wallis with Dunn's multiple comparisons or <sup>b</sup>Fishers exact test. When overall  $p > 0.05$ , multiple comparisons  $p$  values are reported (<sup>†</sup> 20–30 vs. 35–39 years, <sup>¶</sup> 20–30 vs ≥ 40 years, <sup>Δ</sup> 35–39 vs. ≥40 years).

Pregnancy Outcome	20–30 Years (n = 158)	35–39 Years (n = 212)	≥ 40 Years (n = 157)	p value Overall	p Value Multiple Comparisons
APO <sup>b</sup>	13% (21)	14% (30)	17% (26)	0.69	<sup>†</sup> 1.00, <sup>¶</sup> 0.0044, <sup>Δ</sup> 0.020
<i>Pre-Term Birth</i>	3% (5)	4% (9)	4% (6)	0.87	
<i>Small for gestational Age</i>	6% (9)	8% (17)	6% (10)	0.66	
<i>Fetal Growth Restriction</i>	4% (6)	5% (11)	6% (9)	0.71	
<i>Large for Gestational Age</i>	4% (7)	4% (9)	8% (13)	0.19	
<i>Neonatal Intensive Care Unit admission</i>	4% (7)	7% (14)	7% (11)	0.58	
	0% (0)	0% (0)	3% (4)	<b>0.014</b>	
<i>Stillbirth</i>					

Data are mean (range) or percentage (number). Statistical differences are <sup>a</sup>Kruskal-Wallis with Dunn's multiple comparisons or <sup>b</sup>Fishers exact test. When overall  $p > 0.05$ , multiple comparisons  $p$  values are reported (<sup>†</sup> 20–30 vs. 35–39 years, <sup>¶</sup> 20–30 vs ≥ 40 years, <sup>Δ</sup> 35–39 vs. ≥40 years).

Demographic predictors of APO: Univariate logistic regression demonstrated that ex- and current smokers had higher odds of APO than non-smokers (OR 2.00 (95%CI 1.20–3.33) and 4.14 (95%CI 2.01–8.55),  $p = 0.008$  and  $< 0.001$  respectively; Table 3). Multiparity was protective against APO (OR 0.65 (95%CI 0.43-1.00),  $p = 0.048$ ) compared to primiparous women. Maternal ethnicity did not independently affect the risk of APO, although there was a trend towards a protective effect of non-European or Asian ethnicity (“Other” OR of 0.27 (95%CI 0.06–1.16)  $p = 0.08$ ). ART had no detectable effect on outcome (OR 1.08 (95%CI 0.52–2.24)  $p = 0.84$ ). Paternal age had a protective effect against APO (OR 0.54 (95%CI 0.31–0.94)  $p = 0.03$ ). Only the associations between APO and maternal parity or cigarette smoking remained statistically significant after adjusting for maternal ethnicity, parity, smoking status, housing, and paternal age (Table 3).

Table 3

Unadjusted and adjusted odds ratios for prediction of adverse pregnancy outcome of MAMAS participants.

	Unadjusted			Model 1			Model 2		
	OR	95% CI	P value	AOR	95% CI	P value	AOR	95% CI	P value
Ethnicity	Reference	0.27–1.88	0.49	Reference	0.27–2.20	0.63	Reference	0.20–2.00	0.43
<i>European</i>	0.71		0.079	0.77		0.081	0.63		0.12
<i>Asian</i>	0.27	0.06–1.16		0.26	0.06–1.18		0.28	0.06–1.40	
<i>Other</i>									
Parity	Reference	<b>0.43–1.00</b>	0.048	Reference	<b>0.35–0.91</b>	0.019	Reference	<b>0.34–0.91</b>	0.019
<i>Nulliparous</i>	<b>0.65</b>			<b>0.57</b>			<b>0.56</b>		
<i>Multiparous</i>									
ART	Reference	0.52–2.238	0.84	Reference	0.55–2.66	0.64	Reference	0.43–2.30	0.99
<i>None</i>	1.08			1.20			0.99		
<i>ART</i>									
Smoking	Reference	<b>1.20–3.33</b>	0.008	Reference	<b>1.12–3.31</b>	0.018	Reference	<b>1.04–3.17</b>	0.036
No	<b>2.00</b>		< 0.001	<b>1.92</b>		< 0.001	<b>1.82</b>		0.001
Ex	<b>4.14</b>	<b>2.01–8.55</b>		<b>4.76</b>	<b>2.13–10.60</b>		<b>4.34</b>	<b>1.88–9.99</b>	
Current									
Housing	Reference	0.47–1.10	0.12	Reference	0.43–1.18	0.19	Reference	0.38–1.11	0.12
Rented	0.72			0.72			0.65		
Owns									
IMD Quintile	Reference	0.69–2.49	0.40	Reference	0.64–2.39	0.53	Reference	0.69–2.71	0.38
1st	1.31		0.052	1.23		0.028	1.36		0.073
2nd	0.48	0.22–1.00	0.69	<b>0.42</b>	<b>0.64–0.91</b>	0.86	0.48	0.21–1.07	0.86
3rd	1.15	0.58–2.26	0.93	0.94	0.46–1.92	0.80	1.07	0.51–2.24	0.96
4th	0.97			0.91			1.02		
5th		0.50–1.88			0.44–1.87			0.48–2.17	

Model 1 – multivariable logistic regression including all variables except paternal age, Model 2 – multivariable regression additionally adjusting for paternal age. ART = Assistive Reproductive Techniques; IMD = Index of multiple deprivation; IMD Quintile 1st = least deprived, 5th = most deprived. Statistics performed were univariate and multivariable meta-regression. Adjustments included maternal ethnicity, parity, smoking status, housing, and paternal age.

	Unadjusted		Model 1	Model 2		
Paternal Age	Reference	0.39– 1.51	0.45	Reference	0.37– 1.98	0.72
< 30 years		<b>0.30– 0.98</b>			0.23– 1.28	
		<b>0.31– 0.94</b>			0.19– 1.12	
	0.77		0.043	0.86		0.16
	<b>0.54</b>		0.029	0.54		0.08
30– 34 years	<b>0.54</b>			0.46		
35– 39 years						
≥ 40 years						

Model 1 – multivariable logistic regression including all variables except paternal age, Model 2 – multivariable regression additionally adjusting for paternal age. ART = Assistive Reproductive Techniques; IMD = Index of multiple deprivation; IMD Quintile 1st = least deprived, 5th = most deprived. Statistics performed were univariate and multivariable meta-regression. Adjustments included maternal ethnicity, parity, smoking status, housing, and paternal age.

***Nested case-control study to determine whether AMA associated with elevated circulating biomarkers of inflammation and oxidative stress***

The characteristics of participants (n = 40/group) in this nested study are shown in Supplementary Table 2. The three groups differed for factors strongly associated with older age: higher home-ownership in 35–39 and ≥ 40 year olds (95% of ≥ 40 vs. 90% of 35–39 vs. 58% of 20–30 years) and multiparous (78% of ≥ 40 vs. 80% of 35–39 vs. 53% of 20–30 years) and mothers ≥ 40 years had higher previous miscarriage rates (53% vs. 25% of 20–30 years). AMA mothers delivered earlier (by 5–7 days) than 20–30 year olds (p < 0.001; Supplementary Table 3).

Large variation was seen in inflammatory biomarker concentrations in maternal serum. At 28 weeks' gestation, lower circulating concentrations of IL-1α and IL-1RA (p = 0.04 and 0.005, Fig. 2A, E) were measured in mothers 35–39 years compared to 20–30 years, but no significant differences were present between 20–30 and ≥ 40 year olds. Similar trends were apparent at 36 weeks gestation but were not statistically significant. Anti-inflammatory IL-10 was lower in mothers ≥ 40 years at 28 weeks' (p = 0.05), with a stepwise age-related decrease apparent at 36 weeks (p = 0.03, Figs. 2G-H). No differences were seen in IL-1β or TNF-α at 28 weeks or 36 weeks between age groups (Fig. 2). There were no differences in maternal circulating markers of oxidative stress at 28 weeks' gestation (Fig. 3A, C, E). TAC was increased at 36 weeks' gestation in mothers ≥ 40 years compared to controls (p = 0.015; Fig. 3B). No differences of other oxidative stress markers were seen (Fig. 3D and F, Supplementary Fig. 1). Gestational age affected TAC in mothers ≥ 40 s (p = 0.004), whereas 8-isoprostane was positively related to gestational age in all groups (p < 0.001; data not shown). When assessing change in oxidative status over time, TAC levels fell across the third trimester in controls but increased in AMA

women ( $p = 0.005$ ; Fig. 3G). In contrast, elevated lipid peroxidation (8-isoprostane) was apparent in mothers 20–30 and 35–39 years across the third trimester but decreased in women  $\geq 40$  ( $p = 0.04$ ; Fig. 3H). There was a positive relationship between TAC and 8-isoprostane in all participants at 28 weeks' gestation, strongest in women 35–39 years ( $r = 0.61$  vs  $0.45$  in women aged 20–30, Fig. 3I). At 36 weeks a negative correlation existed between TAC and 8-isoprostane in women 35–39 and  $\geq 40$  years ( $r = -0.42$  and  $-0.39$  respectively;  $p = 0.005$  and  $p = 0.01$  Fig. 3J), whereas no relationship was seen in women aged 20–30 ( $r = -0.17$ ,  $p = 0.32$ ).

### ***Nested case-control study to determine whether maternal biomarkers associated with adverse pregnancy outcome in women of AMA***

Women  $\geq 35$  years of age who had APO ( $n = 43$ ) were well matched for demographic variables to women  $\geq 35$  years of age who had a normal pregnancy outcome (Supplementary Table 4). The majority of infants in the APO group were classified as SGA (84%), with 44% under the 5th centile (FGR) (Supplementary Table 5). There were fewer NVDs (39% vs. 65%,  $p = 0.02$ ) and more EMCS (23% vs. 7%,  $p = 0.04$ ) in the APO group compared to NPOs. A quarter of mothers in the APO group delivered preterm ( $< 37$  weeks,  $p < 0.001$ ) and a quarter of infants were admitted to NICU ( $p < 0.001$ ). There were 3 stillbirths included in the APO group (one stillbirth was excluded due to congenital abnormality identified as the cause of death).

There were no differences in circulating cytokines at 28 weeks' or 36 weeks' gestation between AMA women with normal and adverse pregnancy outcome (Supplementary Fig. 2). TAC was higher in AMA mothers with APO compared to normal outcomes at both 28 and 36 weeks' gestation ( $p = 0.002$  and  $0.006$  respectively, Fig. 4A, B). 8-isoprostane increased between 28–36 weeks' gestation in both NPO and APO groups (data not shown). 8-isoprostane also significantly increased in AMA mothers with APO at 28 weeks but was not elevated at 36 weeks' gestation ( $p = 0.01$  and  $p = 0.82$  respectively, Fig. 4E-F). No differences were detected in markers of DNA/RNA damage or protein carbonyl between groups at either 28 weeks ( $p = 0.66$  and  $0.34$  respectively) or 36 weeks' gestation ( $p = 0.57$  and  $0.60$  respectively; Fig. 4C, D, G, H). A positive correlation between TAC and 8-isoprostane at 28 ( $r = 0.46$  for APO and  $0.31$  for NPO) and at 36 weeks with normal outcomes ( $r = -0.39$ ;  $p = 0.01$  Fig. 4J), whereas there was no relationship seen in women with APO ( $r = -0.33$ ,  $p = 0.07$ , Fig. 4I-J).

Concentrations of hPL, PIGF and PIGF:sFlt ratio were unchanged at 28 weeks' gestation (Fig. 5A, C, G). hPL was lower at 36 weeks' gestation in women with APO ( $p = 0.007$ ; Fig. 5B). Similarly, PIGF concentrations were lower at 36 weeks' when measured alone ( $p < 0.001$ , Fig. 5D) or adjusted for sFlt-1 (human VEGF R1/Flt-1) concentrations ( $p = 0.03$ , Fig. 5H). sFlt-1 was lower in women with APO at 28 weeks' with a similar trend at 36 weeks' gestation ( $p = 0.05$  and  $0.07$ , Fig. 5E,F). No differences were detected in circulating hCG, PAPP-A or progesterone with APO (Supplementary Fig. 3). ROC curves were created for all biomarkers that reached a statistical significance of  $p < 0.01$  between NPO and APO. TAC and 8-isoprostane had predictive area under the curve values of  $0.69$  and  $0.66$  respectively (ranked as a poor prognostic markers, Fig. 6A-B), whilst hPL and PIGF had predictive values of  $0.68$  (poor) and  $0.74$  (fair), respectively (Fig. 6C-D).

## **Discussion**

This prospective study found that increased maternal age was associated with increased total antioxidant capacity and a reduction in anti-inflammatory IL-10 and IL-1RA indicating changes in oxidative stress and inflammation over the timeframe of reproductive life span. In mothers  $\geq 35$  years of age, adverse pregnancy

outcome was associated with a further increase in total antioxidant capacity and a reduction in placentally-derived biomarker, hPL and PlGF. In common with large population studies, adverse outcome (most frequently the birth of a small for gestational age infant) was more common in women  $\geq 35$  years of age. In this population, maternal smoking and primiparity were independent risk factors for adverse outcome, consistent with retrospective study findings (7, 10, 38).

## Strengths and Limitations

This prospective study was designed to explore potential mechanisms underpinning the association between AMA and adverse pregnancy outcome, to identify potential biomarkers and generate further hypotheses which can be explored. The multi-centre approach used in this study offered diversity, making it more representative of the UK maternity population. However, this study would have benefitted from larger overall sample size to increase the statistical power to confirm associations between APO and biomarkers and assess the predictive ability of combinations of clinical and biochemical markers. Furthermore, a larger cohort would have enabled larger nested case control studies, with greater statistical power, particularly for cytokine biomarkers which had wide variation in levels between individuals. Despite these limitations, MAMAS is a large prospective study investigating associated factors for adverse pregnancy outcome in AMA and our detailed data collection provided the ability to adjust for multiple confounding variables, and delineate the effects of paternal age, ethnicity and parity and socioeconomic status, all of which may be associated with stillbirth (39–42).

## Interpretation

Understanding the mechanisms underlying the susceptibility to adverse outcomes is essential to improve identification of AMA women highest risk of adverse outcomes. This study focussed on processes implicated in maternal aging and placental dysfunction. A pro-inflammatory bias and elevated oxidative stress are established hallmarks of aging (43–45) and both are strongly associated with pregnancy pathologies, particularly those characterised by placental dysfunction (46–48). The nested case control studies revealed features of biological aging in women of AMA in the absence of adverse outcome including: elevations in TAC, coincident with reduced oxidative damage (reduced lipid peroxidation) and a reduction in anti-inflammatory cytokines (IL-10 and IL-1Ra) possibly indicating a shift towards a pro-inflammatory state. The former findings are consistent with these women delivering healthy infants and suggest that adaptive antioxidant responses are effective in maintaining the oxidant:antioxidant balance protecting against oxidative stress(49). The reduction in IL-10 levels has also been seen in serum and placenta of women perceiving reduced fetal movements (27) and in the placenta of infants with FGR (50). As both FGR and RFM are associated with placental dysfunction, the reduction in IL-10 could be consistent with the increased placental dysfunction seen in AMA mothers (28). Critically, an isolated reduction in anti-inflammatory status is not detrimental, but studies of the IL-10 knockout mouse demonstrate increased susceptibility to inflammatory stimuli resulting in PTB and fetal loss (51), and exacerbation of the vascular symptoms of preeclampsia (52) and effects of hypoxia (53). Therefore, an age-related decline in anti-inflammatory cytokines may increase vulnerability of women of AMA to inflammation and the associated detrimental effects observed on placental function and should therefore be further explored (54). We speculate that maternal aging creates a suboptimal environment for placental and fetal development that contributes to the vulnerability to adverse outcomes.

Consistent with other larger retrospective studies the clinical factors associated with adverse outcome in women of AMA were maternal smoking and primiparity (8, 10, 38). However, in our study population conception by ART had no significant association with stillbirth, although the effect-size of other studies was within the 95% confidence intervals of our population (55, 56). These findings emphasise the need to promote smoking cessation services and suggest that women who have their first pregnancy over the age of 35 or those who smoke should be prioritised for intervention.

In this population APO was associated with higher circulating levels of 8-isoprostane at 28 weeks' gestation, indicating elevated oxidative damage, despite higher antioxidant capacity. Inadequate antioxidant compensatory responses resulting in oxidative stress has been detected in placentas from APO, where it has been related to altered placental function (22). Future studies are required to confirm whether placental oxidative damage is implicated in the placental dysfunction observed in AMA pregnancies.

Consistent with other reports reduced maternal circulating concentrations of placental hormones (hPL, sFlt and PlGF) were detected in AMA pregnancies with APO compared to normal outcomes. The differences in placental hormones provide further evidence for placental dysfunction as an underpinning mechanism for susceptibility to adverse outcomes in women of AMA. There is a growing body of evidence that these represent biomarkers of placental dysfunction, and are lower in pregnancies with FGR, PE and stillbirth (57–59). PlGF and sFlt concentrations in the maternal circulation are correlated with fetal size as early as the first trimester (60) and have strong potential as biomarkers for APO in a clinical setting (59, 61). In common with prognostic accuracy studies from other contexts in pregnancy, PlGF had the strongest predictive value for APO in AMA mothers,(62) although the AUROC is insufficient for clinical utility at present. Further studies with larger sample size are required to determine if a prognostic model incorporating the clinical and biochemical predictors with sufficient predictive power to identify women of AMA at greatest risk of APO can be derived.

## Conclusion

This study has identified alterations in circulating biomarkers of inflammation and oxidative stress markers, in pregnant women of AMA, suggesting that biological processes seen in aging may contribute to susceptibility to adverse outcomes in this population. Furthermore, we identified serum biomarkers with fair predictive accuracy for adverse pregnancy outcome in AMA. With larger sample sizes and data sets, and by combining identified demographic and clinical variables that alter risk of adverse outcome and the measurement of aging and placental biomarkers, it may be possible to create a predictive model with sufficient discrimination to delineate an individual woman's risk of adverse pregnancy outcome relating to AMA. This would allow mothers of AMA to be offered more individualised care that considers both maternal and fetal wellbeing and reduces stillbirth rates whilst minimising unnecessary intervention.

## List Of Abbreviations

AMA Advanced maternal age

AOR Adjusted odds ratio

APO Adverse pregnancy outcome

ART Assisted reproductive technology

AUROC Area under the receiver operator characteristic curve

BMI Body mass index

ELISA Enzyme linked immunosorbent assay

FGR Fetal growth restriction

hPL human placental lactogen

IBC Individualised birthweight centile

IL Interleukin

IMD Index of multiple deprivation

IOL Induction of labour

MAMAS Manchester Advanced Maternal Age Study

NICU Neonatal intensive care unit

OR Odds ratio

PE Preeclampsia

PIGF Placental growth factor

PTB Preterm birth

sFlt1 soluble fms-like tyrosine kinase 1

TNF Tumour necrosis factor

## **Declarations**

### ***Ethics approval and consent to participate***

This study was given a favourable ethical opinion by Greater Manchester South Research Ethics Committee (Ref 12/NW/0015). All participants gave written informed consent prior to participation; all methods were performed in accordance with the relevant guidelines and regulations.

### ***Availability of data and materials***

The datasets generated and/or analysed during the current study are not publicly available as ethical approval was not sought for their dissemination but are available from the corresponding author on reasonable request.

## ***Competing interests***

The authors declare that they have no competing interests

## ***Funding***

This study was funded by Tommy's Charity. The funding source had no involvement in study design, manuscript preparation or decision to publish.

## ***Authors' contributions***

Contribution of Authorship: Conception (AEPH, RLJ, SCL), planning (AEPH, RLJ, SCL), carrying out (SCL), analysing (SCL, SAR, AEPH, RLJ, SCL, SAR), writing up (SCL, RLJ, AEPH).

## ***Acknowledgements***

We would like to thank the participating hospitals in MAMAS study, namely; University Hospital of North Staffordshire: City General Site, Stoke-on-Trent; Leighton Hospital: Women's Health Unit, Crewe; South Warwickshire Foundation NHS Trust, Warwick; Burton Hospitals NHS Foundation Trust: Queens Hospital Burton, Burton-on-Trent; Lincoln County: Clinical Research Facility, Lincoln; and Pilgrim Hospital, Boston. We acknowledge the primary investigators at these sites: Dr. Peter Young, Miss Karren McIntyre, Dr. Nicole Pope, Mr. Olanreqaju Sorinola, Mr. Odiri Oteri and Mr. Sunday Ikhenya for overseeing MAMAS across the UK. Strong thanks must be given to Linda Peacock and Jane Boscolo-Ryan, the Research Midwives in the primary MAMAS site, St. Mary's Hospital, Manchester, who were pivotal in the initiation and progression of MAMAS. Furthermore, we would like to acknowledge the hard work of all the research midwives without whom this study would never have been such a success. Finally, we would like to thank all the mothers who kindly agreed to participate in MAMAS.

## **References**

1. Office of National Statistics. Births by Parents' Characteristics 1938–2016. London: Office of National Statistics; 2018.
2. Royal College Of Obstetricians and Gynaecologists. Induction of Labour at Term in Older Mothers Scientific Impact Paper No. 34. London: Royal College of Obstetricians and Gynaecologists; 2013.
3. Bahtiyar M, Funai E, Norwitz E, Buhimschi C, Rosenberg V, Copel J. Advanced Maternal Age (AMA) is an independent predictor of intrauterine fetal death at term. *Am J Obstet Gynecol.* 2006;195:S209.
4. Carolan M. Maternal age  $\geq 45$  years and maternal and perinatal outcomes: a review of the evidence. *Midwifery.* 2013;29(5):479–89.
5. Cleary-Goldman J, Malone FD, Vidaver J, Ball RH, Nyberg DA, Comstock CH, et al. Impact of maternal age on obstetric outcome. *Obstet Gynecol.* 2005;105(5 Pt 1):983–90.
6. Jahromi BN, Hussein Z. Pregnancy outcome at maternal age 40 and older. *Taiwan J Obstet Gynecol.* 2008;47(3):318–21.
7. Kenny LC, Lavender T, McNamee R, O'Neill SM, Mills T, Khashan AS. Advanced maternal age and adverse pregnancy outcome: evidence from a large contemporary cohort. *PloS one.* 2013;8(2):e56583.


8. Lean SC, Derricott H, Jones RL, Heazell AEP. Advanced maternal age and adverse pregnancy outcomes: A systematic review and meta-analysis. *PloS one*. 2017;12(10):e0186287.
9. Fretts RC. Etiology and prevention of stillbirth. *Am J Obstet Gynecol*. 2005;193(6):1923–35.
10. Flenady V, Koopmans L, Middleton P, Froen JF, Smith GC, Gibbons K, et al. Major risk factors for stillbirth in high-income countries: a systematic review and meta-analysis. *Lancet*. 2011;377(9774):1331–40.
11. Waldenstrom U, Aasheim V, Nilsen AB, Rasmussen S, Pettersson HJ, Schytt E. Adverse pregnancy outcomes related to advanced maternal age compared with smoking and being overweight. *Obstet Gynecol*. 2014;123(1):104–12.
12. Royal College Of Obstetricians and Gynaecologists. Care of Women with Obesity in Pregnancy (Green-top Guideline No. 72). London: RCOG; 2018.
13. Excellence NifHaC. Smoking: stopping in pregnancy and after childbirth (PH26) 2010 [Available from: <https://www.nhs.uk/conditions/pregnancy-and-baby/foods-to-avoid-pregnant/>].
14. Fretts RC, Duru UA. New indications for antepartum testing: making the case for antepartum surveillance or timed delivery for women of advanced maternal age. *Seminars in perinatology*. 2008;32(4):312–7.
15. Johnson JA, Tough S, Sogc Genetics C. Delayed child-bearing. *J Obstet Gynaecol Can*. 2012;34(1):80–93.
16. Walker KF, Bugg G, Macpherson M, McCormick C, Wildsmith C, Smith G, et al. Induction of labour versus expectant management for nulliparous women over 35 years of age: a multi-centre prospective, randomised controlled trial. *BMC pregnancy and childbirth*. 2012;12:145.
17. Walker KF, Bugg GJ, Macpherson M, Thornton J. Induction of labour at term for women over 35 years old: a survey of the views of women and obstetricians. *Eur J Obstet Gynecol Reprod Biol*. 2012;162(2):144–8.
18. Bahtiyar MO, Funai EF, Rosenberg V, Norwitz E, Lipkind H, Buhimschi C, et al. Stillbirth at term in women of advanced maternal age in the United States: when could the antenatal testing be initiated? *Am J Perinatol*. 2008;25(5):301–4.
19. Walker KF, Bugg GJ, Macpherson M, McCormick C, Grace N, Wildsmith C, et al. Randomized Trial of Labor Induction in Women 35 Years of Age or Older. *N Engl J Med*. 2016;374(9):813–22.
20. Al-Gubory KH, Fowler PA, Garrel C. The roles of cellular reactive oxygen species, oxidative stress and antioxidants in pregnancy outcomes. *Int J Biochem Cell Biol*. 2010;42(10):1634–50.
21. Mullins E, Prior T, Roberts I, Kumar S. Changes in the fetal and neonatal cytokine profile in pregnancies complicated by fetal growth restriction. *Am J Reprod Immunol*. 2013;69(5):441–8.
22. Myatt L, Cui X. Oxidative stress in the placenta. *Histochem Cell Biol*. 2004;122(4):369–82.
23. Schetter AJ, Heegaard NH, Harris CC. Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. *Carcinogenesis*. 2010;31(1):37–49.
24. Barja G. The mitochondrial free radical theory of aging. *Prog Mol Biol Transl Sci*. 2014;127:1–27.
25. de Steenwinkel FD, Hokken-Koelega AC, de Man YA, de Rijke YB, de Ridder MA, Hazes JM, et al. Circulating maternal cytokines influence fetal growth in pregnant women with rheumatoid arthritis. *Ann Rheum Dis*. 2013;72(12):1995–2001.
26. Myatt L. Review: Reactive oxygen and nitrogen species and functional adaptation of the placenta. *Placenta*. 2010;31 Suppl:S66-9.

27. Girard S, Heazell AE, Derricott H, Allan SM, Sibley CP, Abrahams VM, et al. Circulating cytokines and alarmins associated with placental inflammation in high-risk pregnancies. *Am J Reprod Immunol*. 2014;72(4):422–34.
28. Lean SC, Heazell AEP, Dilworth MR, Mills TA, Jones RL. Placental Dysfunction Underlies Increased Risk of Fetal Growth Restriction and Stillbirth in Advanced Maternal Age Women. *Scientific reports*. 2017;7(1):9677.
29. Jordan H, Roderick P, Martin D. The Index of Multiple Deprivation 2000 and accessibility effects on health. *Journal of epidemiology and community health*. 2004;58(3):250–7.
30. Gardosi J, Francis A. GROW. 6.7.7 ed. Birmingham: Gestational Network; 2015. p. Customised Weight Centile Calculator.
31. Alberti-Fidanza A, Di Renzo GC, Burini G, Antonelli G, Perriello G. Diet during pregnancy and total antioxidant capacity in maternal and umbilical cord blood. *J Matern Fetal Neonatal Med*. 2002;12(1):59–63.
32. Musolino C, Alonci A, Allegra A, Saija A, Penna G, Cannavo A, et al. Increase in serum protein carbonyl groups is associated with more advanced stage of disease in multiple myeloma patients. *Biomarkers*. 2011;16(8):718–9.
33. Ogawa F, Shimizu K, Muroi E, Hara T, Hasegawa M, Takehara K, et al. Serum levels of 8-isoprostane, a marker of oxidative stress, are elevated in patients with systemic sclerosis. *Rheumatology (Oxford)*. 2006;45(7):815–8.
34. Kikuchi A, Takeda A, Onodera H, Kimpara T, Hisanaga K, Sato N, et al. Systemic increase of oxidative nucleic acid damage in Parkinson's disease and multiple system atrophy. *Neurobiol Dis*. 2002;9(2):244–8.
35. Bartha JL, Romero-Carmona R, Comino-Delgado R. Inflammatory cytokines in intrauterine growth retardation. *Acta Obstet Gynecol Scand*. 2003;82(12):1099–102.
36. Doria A, Cutolo M, Ghirardello A, Zen M, Villalta D, Tincani A, et al. Effect of pregnancy on serum cytokines in SLE patients. *Arthritis Res Ther*. 2012;14(2):R66.
37. Tosun M, Celik H, Avci B, Yavuz E, Alper T, Malatyalioglu E. Maternal and umbilical serum levels of interleukin-6, interleukin-8, and tumor necrosis factor-alpha in normal pregnancies and in pregnancies complicated by preeclampsia. *J Matern Fetal Neonatal Med*. 2010;23(8):880–6.
38. Stacey T, Thompson JM, Mitchell EA, Ekeroma AJ, Zuccollo JM, McCowan LM. Relationship between obesity, ethnicity and risk of late stillbirth: a case control study. *BMC pregnancy and childbirth*. 2011;11:3.
39. Heazell A, Budd J, Smith LK, Li M, Cronin R, Bradford B, et al. Associations between social and behavioural factors and the risk of late stillbirth - findings from the Midland and North of England Stillbirth case-control study. *BJOG*. 2020.
40. Draper ES, Gallimore ID, Kurinczuk JJ, Smith PW, Bobby T, Smith LK, et al. MBRRACE-UK Perinatal Mortality Surveillance Report, UK Perinatal Deaths for Births from January to December 2016 Leicester: The Infant Mortality and Morbidity Studies, Department of Health Sciences, University of Leicester.; 2018.
41. Alio AP, Salihu HM, McIntosh C, August EM, Weldeselasse H, Sanchez E, et al. The effect of paternal age on fetal birth outcomes. *Am J Mens Health*. 2012;6(5):427–35.
42. Astolfi P, De Pasquale A, Zonta LA. Late paternity and stillbirth risk. *Hum Reprod*. 2004;19(11):2497–501.

43. Syslova K, Bohmova A, Mikoska M, Kuzma M, Pelclova D, Kacer P. Multimarker screening of oxidative stress in aging. *Oxid Med Cell Longev*. 2014;2014:562860.
44. Checa J, Aran JM. Reactive Oxygen Species: Drivers of Physiological and Pathological Processes. *J Inflamm Res*. 2020;13:1057–73.
45. Miossec P. Pro- and antiinflammatory cytokine balance in rheumatoid arthritis. *Clin Exp Rheumatol*. 1995;13 Suppl 12:S13-6.
46. Sharps MC, Baker BC, Guevara T, Bischof H, Jones RL, Greenwood SL, et al. Increased placental macrophages and a pro-inflammatory profile in placentas and maternal serum in infants with a decreased growth rate in the third trimester of pregnancy. *Am J Reprod Immunol*. 2020;84(3):e13267.
47. Burton GJ, Jauniaux E. Pathophysiology of placental-derived fetal growth restriction. *Am J Obstet Gynecol*. 2018;218(2S):S745-S61.
48. Tenorio MB, Ferreira RC, Moura FA, Bueno NB, de Oliveira ACM, Goulart MOF. Cross-Talk between Oxidative Stress and Inflammation in Preeclampsia. *Oxid Med Cell Longev*. 2019;2019:8238727.
49. Kaya S, Keskin HL, Kaya B, Ustuner I, Avsar AF. Reduced total antioxidant status in postterm pregnancies. *Hippokratia*. 2013;17(1):55–9.
50. Amu S, Hahn-Zoric M, Malik A, Ashraf R, Zaman S, Kjellmer I, et al. Cytokines in the placenta of Pakistani newborns with and without intrauterine growth retardation. *Pediatric research*. 2006;59(2):254–8.
51. Thaxton JE, Romero R, Sharma S. TLR9 activation coupled to IL-10 deficiency induces adverse pregnancy outcomes. *J Immunol*. 2009;183(2):1144–54.
52. Chatterjee P, Chiasson VL, Kopriva SE, Young KJ, Chatterjee V, Jones KA, et al. Interleukin 10 deficiency exacerbates toll-like receptor 3-induced preeclampsia-like symptoms in mice. *Hypertension*. 2011;58(3):489–96.
53. Lai Z, Kalkunte S, Sharma S. A critical role of interleukin-10 in modulating hypoxia-induced preeclampsia-like disease in mice. *Hypertension*. 2011;57(3):505–14.
54. Da Silva EC, Silva SV, Damiao R, Fonseca EB, Garcia S, Lippi UG. Stress and anxiety in pregnant women exposed to ultrasound. *J Matern Fetal Neonatal Med*. 2011;In Press.
55. Schieve LA, Meikle SF, Ferre C, Peterson HB, Jeng G, Wilcox LS. Low and very low birth weight in infants conceived with use of assisted reproductive technology. *N Engl J Med*. 2002;346(10):731–7.
56. Luke B, Stern JE, Kotelchuck M, Declercq ER, Cohen B, Diop H. Birth Outcomes by Infertility Diagnosis Analyses of the Massachusetts Outcomes Study of Assisted Reproductive Technologies (MOSART). *J Reprod Med*. 2015;60(11–12):480–90.
57. Ranta JK, Raatikainen K, Romppanen J, Pulkki K, Heinonen S. Decreased PAPP-A is associated with preeclampsia, premature delivery and small for gestational age infants but not with placental abruption. *Eur J Obstet Gynecol Reprod Biol*. 2011;157(1):48–52.
58. Dutton PJ, Warrander LK, Roberts SA, Bernatavicius G, Byrd LM, Gaze D, et al. Predictors of poor perinatal outcome following maternal perception of reduced fetal movements—a prospective cohort study. *PloS one*. 2012;7(7):e39784.
59. Kenny LC, Black MA, Poston L, Taylor R, Myers JE, Baker PN, et al. Early pregnancy prediction of preeclampsia in nulliparous women, combining clinical risk and biomarkers: the Screening for Pregnancy


- Endpoints (SCOPE) international cohort study. Hypertension. 2014;64(3):644–52.
60. Bouwland-Both MI, Steegers EA, Lindemans J, Russcher H, Hofman A, Geurts-Moespot AJ, et al. Maternal soluble fms-like tyrosine kinase-1, placental growth factor, plasminogen activator inhibitor-2, and folate concentrations and early fetal size: the Generation R study. *Am J Obstet Gynecol.* 2013;209(2):121 e1-11.
61. Herraiz I, Simon E, Gomez-Arriaga PI, Martinez-Moratalla JM, Garcia-Burguillo A, Jimenez EA, et al. Angiogenesis-Related Biomarkers (sFlt-1/PLGF) in the Prediction and Diagnosis of Placental Dysfunction: An Approach for Clinical Integration. *Int J Mol Sci.* 2015;16(8):19009–26.
62. Heazell AE, Hayes DJ, Whitworth M, Takwoingi Y, Bayliss SE, Davenport C. Biochemical tests of placental function versus ultrasound assessment of fetal size for stillbirth and small-for-gestational-age infants. *Cochrane Database Syst Rev.* 2019;5:CD012245.

## Figures




**Figure 1**

Flow diagram of participant recruitment and retention in the MAMAS cohort study.




**Figure 2**

Circulating inflammatory markers in women grouped by maternal age, n=40/group. Maternal serum at 28 weeks (A, C, E, G, I) and 36 weeks (B, D, F, H, J) gestation concentrations of: (A-B) interleukin (IL-1) $\alpha$ , (C-D) IL-1 $\beta$ , (E-F) IL-1Ra, (G-H) IL-10 and (I-J) TNF $\alpha$ . Data are logarithmically transformed, with median, interquartile range (box) and total range (whiskers) plotted. Analysed using one-way ANOVA (\*p<0.05, \*\*p<0.01).




**Figure 3**

Levels of markers of oxidative stress status in women grouped by maternal age; n=40/group. Maternal serum at 28 weeks (A, C, E) and 36 weeks (B, D, F) gestation was quantified for: (A-B) Total Antioxidant Capacity (TAC), (C-D) 8-Isoprostane and (E-F) protein Carbonyl. Rate of change between 28 and 36 weeks' gestation of: (G) Total Antioxidant Capacity (TAC) and (H) 8-Isoprostane. Data presented as median, interquartile range (box) and total range (whiskers). Analysed using Kruskal-Wallis with Dunn's multiple comparisons or one-way ANOVA on transformed data. TAC was correlated with log 8-isoprostane at (I) 28 weeks and (J) 36 weeks using Spearman rank test (\*p<0.05, \*\*p<0.01), \*\*\* p <0.001).




**Figure 4**

Levels of oxidative stress markers maternal serum from women  $\geq 40$  years of age with normal and adverse pregnancy outcome;  $n=43/\text{group}$ . Maternal serum at 28 weeks (A, C, E, G) and 36 weeks (B, D, F, H) gestation against pregnancy outcome. (A-B) Total Antioxidant Capacity (TAC), (C-D) DNA/RNA damage, (E-F) 8-Isoprostane and (G-H) Protein Carbonyl. Data are (A-B) median, IQR and range, Mann Whitney test or (C-H) unpaired t-test for transformed data. TAC was correlated with 8-isoprostane at (G) 28 weeks and (H) 36 weeks gestation using Spearman rank test (\* $p < 0.05$ , \*\* $p < 0.01$ ).



**Figure 5**

Levels of placental hormones in maternal serum from women  $\geq 40$  years of age with normal and adverse pregnancy outcome ( $n=43/\text{group}$ ). Maternal serum/plasma at 28 weeks (A, C, E, G) and 36 weeks (B, D, F, H) gestation against pregnancy outcome. (A-B) human placental lactogen (hPL), (C-D) placental growth factor (PIGF), (E-F) soluble fms like tyrosine kinase-1 (sFlt) and (G-H) PIGF:sFlt ratio. Data presented as median, interquartile range (box) and total range (whiskers) and analysed using Mann-Whitney U-test (\* $p<0.05$ , \*\* $p<0.01$ , \*\*\* $p<0.005$ ).



**Figure 6**

Predictive values of biomarkers of adverse pregnancy outcome in women of advanced maternal age. ROC curve of (A) TAC (Area under the ROC curve (AUROC) =0.69), (B) 8-Isoprostane (AUROC=0.66), (C) hPL (AUROC=0.68) and (D) PIGF (AUROC=0.74) as predictors of adverse pregnancy outcome.

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SupplementaryFigure1.docx](#)
- [SupplementaryFigure2.docx](#)
- [SupplementaryFigure3.docx](#)
- [SupplementaryTable1.docx](#)
- [SupplementaryTable2.docx](#)
- [SupplementaryTable3.docx](#)
- [SupplementaryTable4.docx](#)
- [SupplementaryTable5.docx](#)